Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Lee's Pharm Forms Second China Cancer Partnership with Beijing Shenogen

publication date: Nov 22, 2017

Lee's Pharm and Beijing Shenogen Pharma announced a second cancer partnership that involves Shenogen's icaritin, a small molecule, TCM-derived treatment currently in China Phase III trials for hepatocellular carcinoma. In the latest joint effort, Lee's Pharm will pair its PD-L1 candidate with icaritin. Lee's in-licensed China rights to the PD-L1 molecule from San Diego's Sorrento Therapeutics. One year ago, Lee's and Shenogen agreed to co-develop a combination of Lee's Pexa-Vec, an oncolytic virus intended for HCC, and icaritin. More details....

Stock Symbols: (HK:0950) (NSDQ: SRNE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.